Longer Duration of Adjuvant Trastuzumab May Further Improve DFS Rates in ERBB2 ...
One year of adjuvant trastuzumab improved disease-free survival (DFS) over 9 weeks in ERBB2-positive breast cancer patients, with no significant difference in overall survival (OS). The 9-week regimen may be an option for patients unable to tolerate or afford 1-year treatment. DFS was shorter in the 9-week group (HR 1.36; 90% CI, 1.14-1.62; P = .004), while OS rates were similar at 5 and 10 years. Factors like docetaxel dose, positive axillary nodes, and disease stage affected DFS, but not OS. Four cardiac deaths occurred, three in the 9-week group. The study included 2176 women, randomized to 9 weeks or 1 year of trastuzumab, with chemotherapy cycles. The 9-week regimen offers benefits like reduced cardiac monitoring, fewer visits, and lower cost, but has limitations such as short follow-up and limited generalizability.
Related Clinical Trials
Highlighted Terms
Related News
One year of adjuvant trastuzumab improved disease-free survival (DFS) over 9 weeks in ERBB2-positive breast cancer patients, with no significant difference in overall survival (OS). The 9-week regimen may be an option for patients unable to tolerate or afford 1-year treatment. DFS was shorter in the 9-week group (HR 1.36; 90% CI, 1.14-1.62; P = .004), while OS rates were similar at 5 and 10 years. Factors like docetaxel dose, positive axillary nodes, and disease stage affected DFS, but not OS. Four cardiac deaths occurred, three in the 9-week group. The study included 2176 women, randomized to 9 weeks or 1 year of trastuzumab, with chemotherapy cycles. The 9-week regimen offers benefits like reduced cardiac monitoring, fewer visits, and lower cost, but has limitations such as short follow-up and limited generalizability.
1-year adjuvant trastuzumab in ERBB2-positive breast cancer patients improved DFS compared to 9-week treatment, with 5-year DFS rates of 90.7% and 87.7%, respectively. Multivariable analysis indicated death risk was associated with positive axillary nodes, age, and disease stage, but not ER status or treatment group. The SOLD trial's findings align with the ShortHER trial, suggesting no interaction between treatment group and axillary nodal metastasis category.